REAL-WORLD EXPERIENCE, SATISFACTION AND EMOTIONAL OUTCOMES OF ONCE WEEKLY SEMAGLUTIDE USERS IN WEIGHT MANAGEMENT
Author(s)
João Fernandes, MSc1, Timothy Arnaut, MSc1, Julie Hahn-Pedersen, MSc1, Daniele Montalto, MSc2, Amira Abdelkhalik, MSc2, Ramota Alaran, PhD2, Freddy Green, MSc2.
1Novo Nordisk A/S, Søborg, Denmark, 2Ipsos UK, London, United Kingdom.
1Novo Nordisk A/S, Søborg, Denmark, 2Ipsos UK, London, United Kingdom.
OBJECTIVES: To characterise the treatment journey for semaglutide users for weight management, focusing on motivations, sources of influence, treatment satisfaction, and impact on emotions and quality of life (QoL).
METHODS: A 20-minute online self-administered bespoke survey was conducted among adults with a BMI ≥ 25kg/m2 across the United Kingdom (UK), Brazil and the Kingdom of Saudi Arabia (KSA), with this analysis focusing on current or former semaglutide users. Data captured weight loss motivators, factors influencing treatment initiation and continuity, information sources, satisfaction, and emotional states.
RESULTS: The study included 268 current (n=78) or former semaglutide (n=190) users (UK, n=79; KSA, n=123; Brazil, n=66). Most were women (53%), aged 38 on average and had a mean BMI of 33kg/m2 at baseline, with over half of respondents paying for semaglutide out of pocket (56%). Weight-loss motivations were primarily health-driven (92%), such as preventing medical conditions. Key information sources on weight-loss management included healthcare professionals (HCPs) (65%) and online platforms (59%). Top deciding factors for users to re-initiate/stay on semaglutide included maintaining desired weight (31%), and QoL improvement (28%). Positive emotional drivers during treatment were reported by 80% of participants, with the most common being reaching desired weight, meeting health milestones, and positive lifestyle changes. In contrast, negative drivers included affordability and social stigma. 66% reported satisfaction with current semaglutide treatment, citing visible weight loss, ease of use, reducing food cravings, boosting self-esteem and energy levels. Overall, 86% reported their QoL improved significantly/a fair amount/somewhat and 76% reported semaglutide as very/fairly effective.
CONCLUSIONS: Semaglutide demonstrates high clinical and patient-centred value, fostering positive emotional transitions and QoL gains. However, affordability constraints and social stigma remain key barriers to access and sustained use. Addressing these challenges, while empowering HCPs to deliver holistic, emotionally and behaviourally supportive care, is critical to improving patient outcomes and realizing long-term health benefits.
METHODS: A 20-minute online self-administered bespoke survey was conducted among adults with a BMI ≥ 25kg/m2 across the United Kingdom (UK), Brazil and the Kingdom of Saudi Arabia (KSA), with this analysis focusing on current or former semaglutide users. Data captured weight loss motivators, factors influencing treatment initiation and continuity, information sources, satisfaction, and emotional states.
RESULTS: The study included 268 current (n=78) or former semaglutide (n=190) users (UK, n=79; KSA, n=123; Brazil, n=66). Most were women (53%), aged 38 on average and had a mean BMI of 33kg/m2 at baseline, with over half of respondents paying for semaglutide out of pocket (56%). Weight-loss motivations were primarily health-driven (92%), such as preventing medical conditions. Key information sources on weight-loss management included healthcare professionals (HCPs) (65%) and online platforms (59%). Top deciding factors for users to re-initiate/stay on semaglutide included maintaining desired weight (31%), and QoL improvement (28%). Positive emotional drivers during treatment were reported by 80% of participants, with the most common being reaching desired weight, meeting health milestones, and positive lifestyle changes. In contrast, negative drivers included affordability and social stigma. 66% reported satisfaction with current semaglutide treatment, citing visible weight loss, ease of use, reducing food cravings, boosting self-esteem and energy levels. Overall, 86% reported their QoL improved significantly/a fair amount/somewhat and 76% reported semaglutide as very/fairly effective.
CONCLUSIONS: Semaglutide demonstrates high clinical and patient-centred value, fostering positive emotional transitions and QoL gains. However, affordability constraints and social stigma remain key barriers to access and sustained use. Addressing these challenges, while empowering HCPs to deliver holistic, emotionally and behaviourally supportive care, is critical to improving patient outcomes and realizing long-term health benefits.
Conference/Value in Health Info
2026-11, ISPOR Europe 2026, Vienna, Austria
Value in Health, Volume 29, Issue 12S
Code
PCR58
Topic
Patient-Centered Research
Topic Subcategory
Patient Behavior and Incentives, Patient-reported Outcomes & Quality of Life Outcomes
Disease
Diabetes/Endocrine/Metabolic Disorders (including obesity), No Additional Disease & Conditions/Specialized Treatment Areas